Lead Program (undisclosed)

About Radiomer Therapeutics

Radiomer Therapeutics is an early-stage biotech pioneering a novel class of targeted radiopharmaceuticals using its Raptamer platform. Raptamers combine the high affinity of antibodies with favorable pharmacokinetics for radiopharmaceutical delivery, enabling rapid development from target identification to clinical entry. The company is on track to initiate its first Phase 0 imaging/dosimetry trial in cancer patients by early 2025, with a pipeline focused on oncology. Backed by Fannin and led by a seasoned management team with extensive drug development experience, Radiomer is positioning itself in the rapidly expanding radiopharmaceutical therapeutics market.

About GliaPharm

GliaPharm is a private, preclinical-stage biotech leveraging decades of glial cell research to develop neuroprotective therapies. The company has established the GliaX technology platform to discover and develop small molecules targeting glial cells, with an initial focus on Alzheimer's disease, epilepsy, and ALS. Backed by a strong scientific foundation from co-founder Prof. Pierre Magistretti and led by an experienced executive team, the company has secured non-dilutive funding, including a $4.2M investment from the Alzheimer's Drug Discovery Foundation (ADDF) in 2023. GliaPharm represents a novel approach in neurology by targeting non-neuronal cells, aiming to address high-unmet-need conditions with limited treatment options.

About BlackfinBio

Blackfin Bio is an early-stage, private biotech company leveraging academic research from the University of Sheffield to build a pipeline of gene therapies targeting neurological diseases. The company's lead program has been de-risked through non-dilutive funding from LifeArc and seed investment from patient groups and angels. Currently in a pre-clinical or discovery stage, Blackfin is actively seeking further investment to advance its research and development efforts towards the clinic.

About Breakthru Medicine

Breakthru Medicine is an early-stage oncology biotech leveraging deep industry expertise and a capital-efficient strategy to tackle resistant solid tumors. Founded by veterans with a collective history of 12 FDA approvals and 8 Breakthrough Therapy designations, the company is advancing a portfolio of innovative therapeutics across antibodies, biologics, small molecules, and drug delivery. Its lead program is targeting clinical trials in early 2027, supported by a discovery platform aimed at accelerating target identification and validation. The company's model is built on data-driven decision-making and a focus on transformative therapies for patients with critical unmet needs.

Therapeutic Areas

Other Oncology Drugs